About HEC CJ PHARM Company

Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company” or “Dongyangguang Changjiang Pharmaceutical”, together with its subsidiaries collectively referred to as the “Group”) is a pharmaceutical enterprise focusing on R&D, production and sales of pharmaceutical products in the treatment fields of anti-infection, endocrine and metabolic treatment, and is a domestic pharmaceutical platform under Dongyangguang Group. The company entered the Chinese pharmaceutical industry through its predecessor, Yichang Changjiang Pharmaceutical Co., Ltd., which was established in 2001. Up to now, the company has a business history of more than 23 years, and its pharmaceutical sales performance and R&D capabilities rank among the leading positions in the domestic pharmaceutical industry. On May 11, 2015, the Company was restructured as a company limited by shares and successfully listed on the main board of the Hong Kong Stock Exchange Limited (“Stock Exchange”) on December 29, 2015, with stock code 01558.HK. Since its establishment, the company has always adhered to the pharmaceutical concept of “serving the Chinese with higher standards”, and has a strong industrial base and leading competitive advantage in pharmaceutical manufacturing and marketing. As of June 30, 2024, the company had a nationwide product distribution network and 1,897 professional sales personnel in China. One of our core products, Kewei (oseltamivir phosphate), is a first-line drug for clinical use against influenza virus in China. Its granular dosage form is our exclusive patented product. Oseltamivir phosphate was included in the “National Catalogue of Essential Medicines (2018 Edition)” in 2018. In 2020, oseltamivir phosphate continued to be selected as the “Influenza Diagnosis and Treatment Plan (2020 Edition)” issued by the General Office of the National Health Commission. In 2023, the company's oseltamivir phosphate products continued to be included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023 Edition)” issued by China's Ministry of Human Resources and Social Security. In addition, the company has established strategic partnership relationships with many well-known pharmaceutical companies; reached a strategic partnership with Sinopharm Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange: 000028.SZ), and the first operating project was officially launched in 2018; signed a strategic cooperation framework agreement with Jiuzhou Tong Pharmaceutical Group Co., Ltd. (“Kyushu Express”). Based on this, the company authorized the product Kewei related specifications to Jiuzhou Tong's exclusive general agency for OTC channels in mainland China; with the Wuhan Institute of Virology of the Chinese Academy of Sciences and National Emergency Prevention and Control The Pharmaceutical Engineering Technology Research Center and Guangdong Dongyangguang Pharmaceutical Co., Ltd. (formerly known as Guangdong Dongyangguang Pharmaceutical Co., Ltd., “Guangdong Dongyangguang Pharmaceutical”) signed an agreement of intent. According to this, the parties will jointly establish a national collaborative industrialization platform for military and civilian integration of emergency prevention and control drugs and a national antiviral drug center. The company believes that the above strategic partnerships will bring ideal development prospects to the company's business. The company always adheres to the development strategy of specialization, branding and differentiation, and is committed to the professional development of the marketing team, steady and innovative market operation and strategic resource integration to build the unique brand characteristics and core competitiveness of “Dongyangyang Changjiang Pharmaceutical” within the industry, and create more value for pharmaceutical consumers and partners. In the future, the company will further enrich the product line, develop markets and improve the international production standards and quality of products, and continue to expand the coverage of marketing and sales scope to promote further growth in the company's business and profitability, and seek higher economic benefits and benefits for investors.